Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label add-on DDI study of FYX-051 and warfarin in Japanese healthy adult males
jRCT2080221293Phase 3
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of topiroxostat in gout, sponsored by Sanwa Kagaku Kenkyusho Co., Ltd. Primary endpoints: Pharmacokinetics of warfarin with FYX-051 co-administration and Safety of warfarin with FYX-051 co-administration.
02
Drugs
topiroxostat
03
Conditions
gout
Beyond the preview
Go deeper on jRCT2080221293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221293.